AAPL   372.69 (-0.31%)
MSFT   208.25 (-1.16%)
FB   240.86 (+0.24%)
GOOGL   1,489.92 (-0.65%)
AMZN   3,000.12 (-1.86%)
NVDA   394.87 (+0.33%)
CGC   16.50 (-2.60%)
BABA   236.51 (-1.45%)
MU   49.09 (-3.59%)
GE   6.76 (-3.43%)
TSLA   1,389.86 (+1.33%)
AMD   52.93 (-0.88%)
T   30.32 (-0.56%)
ACB   12.42 (+1.97%)
F   6.12 (-1.13%)
GILD   76.42 (-0.44%)
DIS   113.63 (-0.69%)
BAC   23.01 (-2.75%)
NFLX   493.16 (-0.13%)
BA   178.88 (-4.81%)
AAPL   372.69 (-0.31%)
MSFT   208.25 (-1.16%)
FB   240.86 (+0.24%)
GOOGL   1,489.92 (-0.65%)
AMZN   3,000.12 (-1.86%)
NVDA   394.87 (+0.33%)
CGC   16.50 (-2.60%)
BABA   236.51 (-1.45%)
MU   49.09 (-3.59%)
GE   6.76 (-3.43%)
TSLA   1,389.86 (+1.33%)
AMD   52.93 (-0.88%)
T   30.32 (-0.56%)
ACB   12.42 (+1.97%)
F   6.12 (-1.13%)
GILD   76.42 (-0.44%)
DIS   113.63 (-0.69%)
BAC   23.01 (-2.75%)
NFLX   493.16 (-0.13%)
BA   178.88 (-4.81%)
AAPL   372.69 (-0.31%)
MSFT   208.25 (-1.16%)
FB   240.86 (+0.24%)
GOOGL   1,489.92 (-0.65%)
AMZN   3,000.12 (-1.86%)
NVDA   394.87 (+0.33%)
CGC   16.50 (-2.60%)
BABA   236.51 (-1.45%)
MU   49.09 (-3.59%)
GE   6.76 (-3.43%)
TSLA   1,389.86 (+1.33%)
AMD   52.93 (-0.88%)
T   30.32 (-0.56%)
ACB   12.42 (+1.97%)
F   6.12 (-1.13%)
GILD   76.42 (-0.44%)
DIS   113.63 (-0.69%)
BAC   23.01 (-2.75%)
NFLX   493.16 (-0.13%)
BA   178.88 (-4.81%)
AAPL   372.69 (-0.31%)
MSFT   208.25 (-1.16%)
FB   240.86 (+0.24%)
GOOGL   1,489.92 (-0.65%)
AMZN   3,000.12 (-1.86%)
NVDA   394.87 (+0.33%)
CGC   16.50 (-2.60%)
BABA   236.51 (-1.45%)
MU   49.09 (-3.59%)
GE   6.76 (-3.43%)
TSLA   1,389.86 (+1.33%)
AMD   52.93 (-0.88%)
T   30.32 (-0.56%)
ACB   12.42 (+1.97%)
F   6.12 (-1.13%)
GILD   76.42 (-0.44%)
DIS   113.63 (-0.69%)
BAC   23.01 (-2.75%)
NFLX   493.16 (-0.13%)
BA   178.88 (-4.81%)
Log in

NASDAQ:AIMTAimmune Therapeutics News Headlines

$16.78
-0.58 (-3.34 %)
(As of 07/7/2020 04:00 PM ET)
Add
Compare
Today's Range
$16.76
Now: $16.78
$17.24
50-Day Range
$16.34
MA: $17.51
$19.00
52-Week Range
$10.09
Now: $16.78
$37.00
Volume982,900 shs
Average Volume1.51 million shs
Market Capitalization$1.09 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.97

Headlines

Aimmune Therapeutics (NASDAQ AIMT) News Headlines

Source:
DateHeadline
Aimmune Appoints Narinder Singh as Executive Vice President of Technical OperationsAimmune Appoints Narinder Singh as Executive Vice President of Technical Operations
finance.yahoo.com - July 6 at 1:31 PM
Cantor Fitzgerald Weighs in on Aimmune Therapeutics Incs FY2021 Earnings (NASDAQ:AIMT)Cantor Fitzgerald Weighs in on Aimmune Therapeutics Inc's FY2021 Earnings (NASDAQ:AIMT)
www.americanbankingnews.com - July 3 at 7:57 AM
Aimmune says patients begin treatment with peanut allergy drug after virus crisisAimmune says patients begin treatment with peanut allergy drug after virus crisis
www.nasdaq.com - July 2 at 6:56 PM
Aimmune Therapeutics Inc (NASDAQ:AIMT) Expected to Post Quarterly Sales of $1.20 MillionAimmune Therapeutics Inc (NASDAQ:AIMT) Expected to Post Quarterly Sales of $1.20 Million
www.americanbankingnews.com - June 29 at 2:06 AM
 Brokerages Anticipate Aimmune Therapeutics Inc (NASDAQ:AIMT) to Post -$1.03 Earnings Per Share Brokerages Anticipate Aimmune Therapeutics Inc (NASDAQ:AIMT) to Post -$1.03 Earnings Per Share
www.americanbankingnews.com - June 27 at 5:22 PM
Aimmune Therapeutics Inc (NASDAQ:AIMT) Given Average Rating of "Buy" by AnalystsAimmune Therapeutics Inc (NASDAQ:AIMT) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - June 24 at 2:25 AM
Hedge Funds Are Buying Aimmune Therapeutics Inc (AIMT)Hedge Funds Are Buying Aimmune Therapeutics Inc (AIMT)
finance.yahoo.com - June 23 at 2:34 PM
Down 40% in 6 Months, Is Aimmune Therapeutics a Buy?Down 40% in 6 Months, Is Aimmune Therapeutics a Buy?
www.fool.com - June 18 at 9:14 AM
Aimmune Therapeutics (NASDAQ:AIMT) Earns News Impact Score of -3.53Aimmune Therapeutics (NASDAQ:AIMT) Earns News Impact Score of -3.53
www.americanbankingnews.com - June 16 at 7:39 PM
Aimmune Therapeutics (NASDAQ:AIMT) Upgraded to "Sell" by BidaskClubAimmune Therapeutics (NASDAQ:AIMT) Upgraded to "Sell" by BidaskClub
www.americanbankingnews.com - June 16 at 5:47 AM
Aimmunes Palforzia shows durable effect in studyAimmune's Palforzia shows durable effect in study
seekingalpha.com - June 8 at 2:06 PM
New Data Show Patients Are Highly Satisfied With and Confident in the Efficacy of Daily Treatment With PALFORZIA™ After Nine MonthsNew Data Show Patients Are Highly Satisfied With and Confident in the Efficacy of Daily Treatment With PALFORZIA™ After Nine Months
finance.yahoo.com - June 8 at 9:06 AM
New Two-Year PALFORZIA™ Data Show On-going Safety and Efficacy and Continued Immunomodulation in Patients with Peanut AllergyNew Two-Year PALFORZIA™ Data Show On-going Safety and Efficacy and Continued Immunomodulation in Patients with Peanut Allergy
finance.yahoo.com - June 8 at 9:06 AM
Aimmune Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare ConferenceAimmune Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare Conference
finance.yahoo.com - June 4 at 12:34 PM
New PALFORZIA™ Data on Long-Term Safety, Efficacy and Immunomodulation and New Data on Patient Satisfaction with PALFORZIA Treatment to be Presented at EAACI 2020 CongressNew PALFORZIA™ Data on Long-Term Safety, Efficacy and Immunomodulation and New Data on Patient Satisfaction with PALFORZIA Treatment to be Presented at EAACI 2020 Congress
finance.yahoo.com - June 1 at 9:41 AM
Largest European Quantitative Study on Peanut Allergy Confirms Significant Need, Burden and Psychosocial Impact of Peanut Allergy on Allergic Individuals and their CaregiversLargest European Quantitative Study on Peanut Allergy Confirms Significant Need, Burden and Psychosocial Impact of Peanut Allergy on Allergic Individuals and their Caregivers
finance.yahoo.com - May 28 at 7:59 AM
Some Analysts Just Cut Their Aimmune Therapeutics, Inc. (NASDAQ:AIMT) EstimatesSome Analysts Just Cut Their Aimmune Therapeutics, Inc. (NASDAQ:AIMT) Estimates
finance.yahoo.com - May 19 at 10:21 AM
The Play On Aimmune TherapeuticsThe Play On Aimmune Therapeutics
seekingalpha.com - May 18 at 1:28 PM
Why Are So Many Traders Betting Against the First Therapy for Peanut Allergies?Why Are So Many Traders Betting Against the First Therapy for Peanut Allergies?
finance.yahoo.com - May 16 at 8:45 AM
Aimmune Therapeutics (NASDAQ:AIMT)  Shares Down 7.3%  on Analyst DowngradeAimmune Therapeutics (NASDAQ:AIMT) Shares Down 7.3% on Analyst Downgrade
www.marketbeat.com - May 13 at 6:54 PM
Aimmune Therapeutics to Present at the RBC Capital Markets 2020 Global Healthcare ConferenceAimmune Therapeutics to Present at the RBC Capital Markets 2020 Global Healthcare Conference
www.marketwatch.com - May 12 at 5:44 PM
Edited Transcript of AIMT earnings conference call or presentation 11-May-20 8:30pm GMTEdited Transcript of AIMT earnings conference call or presentation 11-May-20 8:30pm GMT
finance.yahoo.com - May 12 at 7:40 AM
Is Aimmune Therapeutics (NASDAQ:AIMT) Weighed On By Its Debt Load?Is Aimmune Therapeutics (NASDAQ:AIMT) Weighed On By Its Debt Load?
finance.yahoo.com - May 12 at 7:40 AM
Aimmune Therapeutics, Inc. (AIMT) CEO Jayson Dallas on Q1 2020 Results - Earnings Call TranscriptAimmune Therapeutics, Inc. (AIMT) CEO Jayson Dallas on Q1 2020 Results - Earnings Call Transcript
seekingalpha.com - May 12 at 2:39 AM
Aimmune Therapeutics Inc (AIMT) Q1 2020 Earnings Call TranscriptAimmune Therapeutics Inc (AIMT) Q1 2020 Earnings Call Transcript
finance.yahoo.com - May 12 at 2:39 AM
Aimmune Therapeutics (AIMT) Reports Q1 Loss, Misses Revenue EstimatesAimmune Therapeutics (AIMT) Reports Q1 Loss, Misses Revenue Estimates
finance.yahoo.com - May 11 at 9:38 PM
Aimmune Therapeutics Announces First Quarter 2020 Financial Results and Provides Recent Operational HighlightsAimmune Therapeutics Announces First Quarter 2020 Financial Results and Provides Recent Operational Highlights
finance.yahoo.com - May 11 at 4:27 PM
Aimmune Therapeutics Q1 Earnings PreviewAimmune Therapeutics Q1 Earnings Preview
seekingalpha.com - May 10 at 10:27 PM
Aimmune Therapeutics Beats DBV Technologies In Multi-Billion Dollar Market To Treat Peanut AllergiesAimmune Therapeutics Beats DBV Technologies In Multi-Billion Dollar Market To Treat Peanut Allergies
seekingalpha.com - May 6 at 2:14 AM
Aimmune Therapeutics to Host Conference Call and Webcast to Discuss First Quarter 2020 Financial Results and Recent Operational HighlightsAimmune Therapeutics to Host Conference Call and Webcast to Discuss First Quarter 2020 Financial Results and Recent Operational Highlights
finance.yahoo.com - April 30 at 6:14 PM
Aimmune: Current Lows Look Attractive, But Coronavirus May Play SpoilsportAimmune: Current Lows Look Attractive, But Coronavirus May Play Spoilsport
seekingalpha.com - April 23 at 1:10 PM
Is Aimmune Therapeutics a Buy?Is Aimmune Therapeutics a Buy?
www.fool.com - April 17 at 8:04 AM
A Tale of 2 Biotechs With Competing Peanut Allergy TreatmentsA Tale of 2 Biotechs With Competing Peanut Allergy Treatments
www.fool.com - April 16 at 2:50 PM
Aimmune Therapeutics to Present at the 19th Annual Needham Virtual Healthcare ConferenceAimmune Therapeutics to Present at the 19th Annual Needham Virtual Healthcare Conference
finance.yahoo.com - April 8 at 9:13 AM
Should You Avoid Aimmune Therapeutics Inc (AIMT)?Should You Avoid Aimmune Therapeutics Inc (AIMT)?
finance.yahoo.com - April 7 at 4:41 PM
Independent Director Patrick Enright Just Bought Shares In Aimmune Therapeutics, Inc. (NASDAQ:AIMT)Independent Director Patrick Enright Just Bought Shares In Aimmune Therapeutics, Inc. (NASDAQ:AIMT)
finance.yahoo.com - March 22 at 12:34 PM
Friday 3/20 Insider Buying Report: AIMT, DXFriday 3/20 Insider Buying Report: AIMT, DX
www.nasdaq.com - March 20 at 1:33 PM
Peanut allergy patients ready for Peninsula companys new drug as COVID-19 slows launchPeanut allergy patients ready for Peninsula company's new drug as COVID-19 slows launch
www.bizjournals.com - March 18 at 12:13 AM
Peanut allergy patients ready for Peninsula company's new drug as COVID-19 slows launchPeanut allergy patients ready for Peninsula company's new drug as COVID-19 slows launch
finance.yahoo.com - March 18 at 12:13 AM
Aimmune says peanut allergy therapy launch may be slowed down by coronavirusAimmune says peanut allergy therapy launch may be slowed down by coronavirus
www.nasdaq.com - March 16 at 11:09 PM
First U.S. patients treated with Palforzia for peanut allergyFirst U.S. patients treated with Palforzia for peanut allergy
seekingalpha.com - March 16 at 12:54 PM
Aimmune Announces First U.S. Patients Are Being Treated with Newly-Approved PALFORZIA™, the First Treatment for Peanut AllergyAimmune Announces First U.S. Patients Are Being Treated with Newly-Approved PALFORZIA™, the First Treatment for Peanut Allergy
finance.yahoo.com - March 16 at 12:54 PM
Aimmunes Palforzia shows durable effect in follow-on peanut allergy studyAimmune's Palforzia shows durable effect in follow-on peanut allergy study
seekingalpha.com - March 14 at 12:54 PM
Aimmune Announces New PALFORZIA™ Data Suggesting Increased Desensitization, Improved Tolerability and Continued Immunomodulation After 18 and 24 Months of TreatmentAimmune Announces New PALFORZIA™ Data Suggesting Increased Desensitization, Improved Tolerability and Continued Immunomodulation After 18 and 24 Months of Treatment
finance.yahoo.com - March 13 at 8:25 PM
Edited Transcript of AIMT earnings conference call or presentation 27-Feb-20 9:30pm GMTEdited Transcript of AIMT earnings conference call or presentation 27-Feb-20 9:30pm GMT
finance.yahoo.com - March 11 at 1:04 PM
One Call Still Sees a Double-Your-Money Upside from the Peanut Allergy TreatmentOne Call Still Sees a Double-Your-Money Upside from the Peanut Allergy Treatment
247wallst.com - March 3 at 7:25 PM
Aimmunes Launch of Peanut Allergy Drug Will Take TimeAimmune's Launch of Peanut Allergy Drug Will Take Time
www.fool.com - February 28 at 10:51 PM
Aimmune Therapeutics Inc (AIMT) Q4 2019 Earnings Call TranscriptAimmune Therapeutics Inc (AIMT) Q4 2019 Earnings Call Transcript
www.fool.com - February 28 at 2:00 AM
Aimmune Therapeutics: 4Q Earnings SnapshotAimmune Therapeutics: 4Q Earnings Snapshot
finance.yahoo.com - February 27 at 7:28 PM
Aimmune Therapeutics Q4 Earnings PreviewAimmune Therapeutics Q4 Earnings Preview
seekingalpha.com - February 26 at 10:50 PM
This page was last updated on 7/7/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.